表达 HER2 的晚期实体瘤中的 IKS014
确定 IKS014(一种 HER2 靶向抗体药物偶联物 (ADC))在晚期 HER2+ 实体瘤参与者中的安全性、耐受性、最大耐受剂量和初步抗肿瘤活性的 1 期剂量递增试验
This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.
研究概览
详细说明
The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). The dose-escalation part (Part 1) of the study is to evaluate the safety and tolerability of increasing dose levels of IKS014 to establish a recommended phase 2 dose (RP2D); and the dose-expansion part (Part 2) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of IKS014 at the RP2D.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:David Browning
- 电话号码:+1-615-975-7776
- 邮箱:david.browning@iksuda.com
学习地点
-
-
-
Singapore、新加坡
- 招聘中
- National Cancer Centre Singapore
-
首席研究员:
- Jing Ying Tira Tan, MBBS
-
Singapore、新加坡
- 招聘中
- Tan Tock Seng Hospital
-
首席研究员:
- Yue Ming Valerie Heong, MBBS
-
-
-
-
-
Auckland、新西兰
- 招聘中
- Auckland City Hospital
-
首席研究员:
- Jane So, MBChB
-
-
-
-
New South Wales
-
Concord、New South Wales、澳大利亚、2139
- 招聘中
- Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit
-
首席研究员:
- Tam Bui, MD
-
Sydney、New South Wales、澳大利亚、2109
- 招聘中
- Macquarie University
-
首席研究员:
- Dhanusha Sabanathan, MD
-
Westmead、New South Wales、澳大利亚、2145
- 招聘中
- Westmead Hospital
-
首席研究员:
- Adnan Nagrial, MD
-
-
Victoria
-
Frankston、Victoria、澳大利亚、3199
- 招聘中
- Peninsula & South Eastern Haematology and Oncology Group (PSEHOG)
-
首席研究员:
- Vinod Ganju, MD
-
Melbourne、Victoria、澳大利亚、3004
- 招聘中
- Alfred Health
-
首席研究员:
- Malaka Ameratunga, MD
-
-
Western Australia
-
Nedlands、Western Australia、澳大利亚、6009
- 招聘中
- Linear Clinical Research
-
首席研究员:
- Peter Lau, MD
-
-
-
-
California
-
Newport Beach、California、美国、92663
- 招聘中
- Hoag Memorial Hospital Presbyterian
-
首席研究员:
- Monica Mita, MD
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- 招聘中
- Dana Farber Cancer Institute
-
首席研究员:
- Nancy Lin, MD
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 招聘中
- Tennessee Oncology
-
首席研究员:
- Jeffrey Russell, MD
-
-
Texas
-
Fort Worth、Texas、美国、76104
- 招聘中
- START Dallas - Fort Worth
-
首席研究员:
- Henry Xiong, MD
-
接触:
- Hope Team
- 邮箱:hopeteam@startresearch.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
-
HER2 positive solid tumors with expression defined as IHC3+, IHC2+/ISH+, or low HER2 expression defined as IHC2+ (ISH-) or IHC1+ (ISH- /+ or untested).
-
Participants with HR positive BC must have received prior treatment with a CDK4/6 inhibitor, in countries where this is standard therapy.
-
Platelets ≥ 75,000 /mcL
-
Hemoglobin ≥ 9.0 g/dL
-
Absolute neutrophil count ≥ 1000/mcL
-
No administration of granulocyte colony-stimulating factor (G-CSF) is allowed within 2 weeks prior to first study drug administration
-
Creatinine clearance > 45/mL/min (using the Cockcroft-Gault equation)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 3 x institutional upper limit of normal (ULN) ≤ 5 x ULN if liver metastases present
-
Total bilirubin ≤ 1.5 x ULN if no liver metastases or < 3 x ULN with Gilbert's Syndrome or liver metastases at baseline
-
Albumin > 2.5 g/dL
-
Prothrombin time or international normalized ratio (INR) and either partial thromboplastin time (PTT) or activated (a) PTT ≤ 1.5 x ULN, ≤ 3 x institutional ULN if anticoagulated.
-
Must have adequate treatment washout period before trial treatment, defined as: Major surgery (≥ 4 weeks) and radiation therapy (≥ 3 weeks; in case of palliative radiation ≥ 2 weeks)
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (or equivalent Karnofsky PS)
-
Part 2 Dose Expansion Cohorts May Include:
- Advanced or metastatic BC that is confirmed HER2-positive defined as IHC 3+ or IHC 2+ and evidence of HER2 amplification by ISH, as per ASCO-CAP and previously treated with at least two HER2 directed treatments.
- Advanced or metastatic BC that has low HER2 expression defined as IHC2+ (ISH-) or IHC1+ (ISH-/+ or untested) and previously treated with at least 1 prior line of therapy which may include chemotherapy and/or a HER2 directed ADC.
- Advanced or metastatic GC or GEJ cancer that is confirmed HER2-positive defined as IHC 3+ or IHC 2+ and evidence of HER2 amplification by ISH as per ASCO-CAP and previously treated with at least 1 prior line of therapy, which may include chemotherapy and/or a HER2 directed ADC.
- Advanced or metastatic solid tumor that has been treated with standard of care therapy and is HER2 positive (HER2 IHC3+) as per ASCO-CAP or metastatic NSCLC (that has been treated with standard of care therapy) with a known activating HER2 (ERBB2) mutation.
- Advanced or metastatic adenocarcinoma of the Esophagus that has been treated with at least one prior line of standard treatment, which may have included a HER2-directed therapy. The tumor must be HER2 positive defined either HER2 IHC3+ or HER2 IHC 2+/ISH+.
Key Exclusion Criteria:
-
History of (noninfectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
-
Any clinically apparent ≥ Grade 2 pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e., pulmonary emboli within three months of the trial enrollment, severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease, pleural effusion, etc.), and any autoimmune, connective tissue or inflammatory disorders with potential pulmonary involvement (e.g., rheumatoid arthritis, Sjogren's, sarcoidosis), or prior pneumonectomy.
-
Current evidence of ≥ Grade 2 keratitis or other corneal abnormality.
-
Evidence of a clinically significant (≥ Grade 2) abnormality on slit-lamp examination or other clinically significant ophthalmologic finding, as determined by an ophthalmologist.
-
Evidence of clinically significant (≥ Grade 2) confluent superficial keratitis, a corneal epithelial defect, a corneal ulcer, or stromal opacity.
-
Participant must not use contact lenses while participating in this study.
-
Central nervous system metastatic disease unless treated with definitive local therapy (surgical resection, stereotactic radiotherapy, or whole brain radiotherapy) and participant is clinically, radiologically and neurologically stable for at least 4 weeks prior to the first dose of study drug not on steroid therapy or are on a stable or decreasing dose of steroids for at least 7 days prior to first dose of study drug. Prophylactic anticonvulsant medications are allowed.
-
Active second malignancy or history of another malignancy within the last 2 years with the exception of:
- Treated, non-melanoma skin cancers
- Treated carcinoma in situ (CIS) (e.g., breast, cervix)
- Controlled, superficial carcinoma of the urinary bladder
- T1a or b carcinoma of the prostate treated according to local standard of care, with prostate specific antigen (PSA) within normal limits (WNL) for the institution
- Papillary thyroid carcinoma Stage I treated surgically for cure
-
Clinically significant cardiovascular disease or condition
-
Clinically significant liver disease
-
Any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever > 38ºC within 2 weeks prior to first trial drug administration.
-
Any other serious, life-threatening, or unstable preexisting medical condition (aside from the underlying malignancy), including significant organ system dysfunction, or clinically significant laboratory abnormality(ies), which, in the opinion of the Investigator, would either compromise the participant's safety or interfere with obtaining informed consent, compliance with trial procedures, or evaluation of the safety of the trial drug.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Dose Escalation Cohort (Part 1)
Each patient will receive repeat doses (by intravenous (IV) infusions) on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
|
实验性的:Dose Expansion: HER2+ Breast Cancer Participants
Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
|
实验性的:Dose Expansion: HER2 Low Breast Cancer Participants
Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
|
实验性的:Dose Expansion: HER2+ Gastric Cancer or Gastro-esophageal Junction Participants
Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
|
实验性的:Dose Expansion: HER2 Low Gastric Cancer or Gastro-esophageal Junction Participants
Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
|
实验性的:Dose Expansion: HER2 Solid Tumor Cancer Participants
Each patient will receive IKS014 at the recommended dose defined in Part 1 on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criteria is met. |
IKS014 is a human monoclonal antibody (Ab) targeting HER2 linked to monomethyl auristatin F (MMAF) cytotoxic agent. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Recommended Phase 2 Dose (Part 1)
大体时间:Up to 24 months
|
Based on tolerability, preliminary anti-tumor activity, and pharmacokinetics |
Up to 24 months
|
|
Objective Response Rate (Part 2)
大体时间:Up to 24 months
|
Anti-tumor activity will be assessed by RECIST 1.1 |
Up to 24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective Response Rate (Part 1)
大体时间:Up to 24 months
|
Anti-tumor activity will be assessed by RECIST 1.1 |
Up to 24 months
|
|
Plasma Concentrations of IKS014 (Part 1 and 2)
大体时间:Up to 48 months
|
Pharmacokinetic parameters will be determined from observed concentrations of IKS014 |
Up to 48 months
|
|
Evaluation of the immunogenicity of IKS014 (Part 1 and 2)
大体时间:Up to 48 months
|
Occurrence of ADA measured in serum at selected timepoints during the study |
Up to 48 months
|
合作者和调查者
调查人员
- 研究主任:James O'Leary, MD、Iksuda Therapeutics
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.